AU2021206021A1 - Oral solid cannabinoid oil composition for treating gastrointestinal disorders - Google Patents

Oral solid cannabinoid oil composition for treating gastrointestinal disorders Download PDF

Info

Publication number
AU2021206021A1
AU2021206021A1 AU2021206021A AU2021206021A AU2021206021A1 AU 2021206021 A1 AU2021206021 A1 AU 2021206021A1 AU 2021206021 A AU2021206021 A AU 2021206021A AU 2021206021 A AU2021206021 A AU 2021206021A AU 2021206021 A1 AU2021206021 A1 AU 2021206021A1
Authority
AU
Australia
Prior art keywords
cannabinoid oil
cannabinoid
oil
microcrystalline cellulose
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021206021A
Other languages
English (en)
Inventor
Fred Hassan
Syed M Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Original Assignee
Societe des Produits Nestle SA
Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe des Produits Nestle SA, Nestle SA filed Critical Societe des Produits Nestle SA
Publication of AU2021206021A1 publication Critical patent/AU2021206021A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2021206021A 2020-01-08 2021-01-08 Oral solid cannabinoid oil composition for treating gastrointestinal disorders Pending AU2021206021A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062958392P 2020-01-08 2020-01-08
US62/958,392 2020-01-08
PCT/EP2021/050245 WO2021140183A1 (en) 2020-01-08 2021-01-08 Oral solid cannabinoid oil composition for treating gastrointestinal disorders

Publications (1)

Publication Number Publication Date
AU2021206021A1 true AU2021206021A1 (en) 2022-06-02

Family

ID=74236138

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021206021A Pending AU2021206021A1 (en) 2020-01-08 2021-01-08 Oral solid cannabinoid oil composition for treating gastrointestinal disorders

Country Status (8)

Country Link
US (2) US12186281B2 (https=)
EP (1) EP4087547A1 (https=)
JP (1) JP2023509675A (https=)
CN (1) CN114845705A (https=)
AU (1) AU2021206021A1 (https=)
BR (1) BR112022010335A2 (https=)
CA (1) CA3164489A1 (https=)
WO (1) WO2021140183A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021417405A1 (en) * 2021-01-08 2023-06-22 Société des Produits Nestlé S.A. Oral solid cannabinoid oil composition for treating central nervous system disorders
WO2023092079A1 (en) * 2021-11-19 2023-05-25 Bryant Cynthia W Use of cannabinoid compounds to treat gastrointestinal disorders
GB2618322A (en) * 2022-04-29 2023-11-08 113 Botanicals Ltd Compositions and methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120231083A1 (en) * 2010-11-18 2012-09-13 The Board Of Trustees Of The University Of Illinois Sustained release cannabinoid medicaments
US8808736B2 (en) * 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
WO2012109216A1 (en) * 2011-02-11 2012-08-16 Zx Pharma, Llc Multiparticulate l-menthol formulations and related methods
US8758826B2 (en) * 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
CA2909591C (en) * 2013-04-23 2017-03-28 Zx Pharma, Llc Enteric coated multiparticulate composition with proteinaceous subcoat
AU2017216928B2 (en) 2016-02-11 2018-09-20 Gelpell Ag Oral solid cannabinoid formulations, methods for producing and using thereof
US20190091198A1 (en) * 2016-03-28 2019-03-28 Lihi BAR-LEV SCHLEIDER Cannabionid and cannabis-based compositions and methods for the treatment of inflammatory conditions of the gastrointestinal tract
WO2017193072A1 (en) 2016-05-06 2017-11-09 Harvest Direct Enterprises Llc The manufacturing methods, compositions, and medical applications of orally administered cannabis pharmaceuticals
MX382609B (es) * 2016-07-25 2025-03-13 Canopy Growth Corp Nuevas formulaciones y composiciones de cannabis en comprimidos y métodos para su elaboración.
CA3036585A1 (en) 2016-09-27 2018-04-05 CannTab Therapeutics Limited Sustained release cannabinoid formulations
US20200163931A1 (en) 2016-10-12 2020-05-28 Columbia Care Llc Oral composition of extracted cannabinoids and methods of use thereof
CN108853079A (zh) * 2017-05-15 2018-11-23 汉义生物科技（北京）有限公司 大麻素类化合物在治疗肠易激综合征中的应用
CA3078549A1 (en) * 2017-10-05 2019-04-11 Receptor Holdings, Inc. Rapid onset and extended action plant-based and synthetic cannabinoid formulations
WO2019082171A1 (en) * 2017-10-27 2019-05-02 Alvit Pharma ORAL CANNABINOID COMPOSITIONS HAVING ENHANCED BIOAVAILABILITY
WO2019234743A1 (en) 2018-06-06 2019-12-12 Icdpharma Ltd. Anti-inflammatory synergistic compositions comprising cannabinoids and licorice
GB2584341B (en) * 2019-05-31 2023-03-01 Gw Res Ltd Cannabinoid formulations

Also Published As

Publication number Publication date
US20210205235A1 (en) 2021-07-08
US12186281B2 (en) 2025-01-07
US11717494B2 (en) 2023-08-08
BR112022010335A2 (pt) 2022-08-16
JP2023509675A (ja) 2023-03-09
WO2021140183A1 (en) 2021-07-15
CA3164489A1 (en) 2021-07-15
US20230065736A1 (en) 2023-03-02
CN114845705A (zh) 2022-08-02
EP4087547A1 (en) 2022-11-16

Similar Documents

Publication Publication Date Title
JP6105761B2 (ja) 腸溶性被覆されたマルチ粒子徐放性ペパーミントオイル組成物及び関連方法
US11717494B2 (en) Oral solid cannabinoid oil composition for treating gastrointestinal disorders
US9707260B2 (en) Enteric coated multiparticulate controlled release peppermint oil composition and related methods
US11207276B2 (en) Multiparticulate L-menthol formulations and related methods
CN105267172B (zh) 简易制备结肠炎和克罗恩病用高载药量缓释制剂的方法
WO2021001860A1 (en) Pharmaceutical compositions of boswellia serrata
US20160045442A1 (en) Stable pharmaceutical compositions of mesalamine
US20240050377A1 (en) Oral solid cannabinoid oil composition for treating central nervous system disorders
Singh et al. Development of biphasic pulsatile release mini-tablets system of poorly water soluble carvedilol phosphate
AU2015203894A1 (en) Enteric coated multiparticulate controlled release peppermint oil composition and related methods